Paolo Tarantino: List for the upcoming early-phase ADCs at ESMO24

Paolo Tarantino shared a post by Raffaele Colombo on X, adding:

“Terrific list of ADC data to be presented at ESMO24. Most abstracts already available Some showing impressive response rates in hard-to-treat cancers.”

Quoting Raffaele Colombo:

“Slightly updated list for the upcoming early-phase ADCs at ESMO24.”

Source: Paolo Tarantino/X and Raffaele Colombo/X

Raffaele Colombo, a leading figure in the pharmaceutical industry is the Associate Director of Medicinal Chemistry at Zymeworks Inc.. His leadership and scientific acumen drive the discovery and optimization of novel drug candidates and advancing the treatment landscape for various diseases.

Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a  publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.